http://dx.doi.org/10.1007/s12630-016-0805-9
Access to Controlled Medicines for Anesthetic and Surgical Care in Low-Income Countries: A Narrative Review of International Drug Control Systems and Policies

**Short title:** Access to Controlled Medicines for Anesthesia

Jason W. Nickerson,1 Katherine Pettus,2 Kathleen E. Wheeler,3 Christopher Hallam,4 David R. Bewley-Taylor,4 Amir Attaran,5 Adrian W. Gelb6

1Bruyère Research Institute,  
85 Primrose Ave.,  
Ottawa, Ontario  
K1R 6M1  
Canada

2International Association of Hospice and Palliative Care,  
5535 Memorial Dr. Suite F - PMB 509  
Houston TX 77007 USA

3Faculty of Medicine,  
University of Ottawa,  
451 Smyth Rd.,  
Ottawa, Ontario,  
K1H 8M5  
Canada

4Global Drug Policy Observatory,  
Research Institute for Arts and Humanities,  
Room 202 James Callaghan Building,  
Swansea University,  
Singleton Park,  
Swansea,  
SA2 8PP  
Wales

5Faculties of Law and Medicine,  
University of Ottawa,  
1 Stewart St.,  
Ottawa, ON  
K1N 6N5
Adrian W. Gelb
Department of Anesthesia & Perioperative Care
University of California San Francisco
500 Parnassus Ave, 4MUE
San Francisco, CA 94143

Correspondence to: Jason Nickerson (jason@jasonnickerson.ca). Phone: +1 (613) 562-6262 ext. 2906

Funding: None

Disclosure of Interests: All authors are actively engaged in preventing attempts to restrict ketamine globally
**Implication statement:** Safe anesthetic care necessarily requires access to controlled medicines, which are often unavailable in low- and middle-income countries. This article reviews pertinent national and international barriers to accessing controlled medicines and aims to improve anesthesiologists’ understanding of how to strengthen global perioperative care.
Abstract

Purpose: This article describes the functioning of the international drug control system, its integration into national legislation and policy, and the collective impact on access to medicines.

Source: We conducted a review of the three international drug control conventions, peer-reviewed articles and grey literature known to the authors that describes national and international drug control systems and their impact on access to controlled medicines. This was supplemented with literature derived from a structured search of MEDLINE for articles related to medical uses of ketamine in low- and middle-income countries, conducted to strengthen an advocacy campaign. We illustrate the impact of the drug control system on access to medicines through an analysis of current levels of availability of opioids in many countries, as well as through a description of the ongoing advocacy work to ensure the availability of ketamine for medical care in low-income countries.

Principal Findings: The complexity of the international drug control system, and health providers’ lack of knowledge regarding key provisions, presents a barrier to improving access to safe anaesthetic care in low- and middle-income countries. Fifteen of the 46 essential medicines of potential relevance to perioperative care are listed under one or more of the schedules of the three international drug control conventions and are, subsequently, required to be under national controls, potentially decreasing their availability for medical use.

Conclusion: Improving the capacity and quality of anesthetic care in low- and middle-income countries requires attention to improving access to controlled medicines. Anesthesiologists and others involved in global health work should collaborate with policymakers and others to improve national and international drug control legislation to ensure that attempts to thwart illicit drug trafficking and use do not compromise availability of controlled medicines.
Introduction

It is estimated that up to 313 million surgical procedures are performed annually worldwide, of which only approximately 6% occur in low- and lower-middle-income countries (as defined by the World Bank), though they are home to 37% of the world’s population.\textsuperscript{1-3} Estimates of the global burden of disease treatable by surgery vary significantly, and few studies provide population-level surveys or data. The estimates that do exist, however, suggest that surgical conditions (including common conditions such as trauma, malignancies, congenital anomalies, complications of pregnancy, cataracts, and perinatal conditions) comprise between 11-32% of the global burden of disease.\textsuperscript{4-6} These data demonstrate that the low volume of surgical procedures performed in low-income countries does not correspond to the need. Rather, a significant gap in access to surgery exists with over 5 billion people lacking access to safe, affordable surgical and anesthetic care. To fill this gap, an additional 143 million procedures per year would need to be conducted to save lives and prevent disability.\textsuperscript{2}

Provision of safe surgical care requires access to safe anesthesia. Unfortunately, the availability of anesthetic care is hindered by a lack of trained providers, anesthetic equipment, basic infrastructure, and essential medicines. Attempts to quantify these gaps have revealed an anesthetic workforce that is up to a hundred times smaller per capita in low-income versus high-income countries, with grossly insufficient access to basic equipment such as pulse oximetry, and anesthetic medicines.\textsuperscript{5-8}

To better understand the reasons for the global surgery gap, we propose examining one of the likely drivers of poor access to anesthetic care: access to controlled medicines. Many commonly used anesthesia medicines, such as potent analgesics, hypnotics, and others, are essential to the provision of anesthetic and perioperative care and pain management. However, recent estimates suggest that roughly 5.5 billion people, or three quarters of the world’s population, live in countries with very-low, or non-existent, access to opioid analgesics.\textsuperscript{8} This critical deficit is likely an important contributor to the global surgical gap.\textsuperscript{9} We say “likely” because we are aware of no empirical studies that demonstrate this gap. The authors’ and others’ abundant experience, however, suggests that anesthetic medicines are often in short supply in developing countries, and that controlled medicines such as morphine are frequently unavailable or under-utilized.

There have been few, if any, attempts to systematically understand the unique drivers of poor access to pharmaceutical products for anesthetic care in low- and middle-income countries (LMIC).\textsuperscript{10} Despite this, several reports have documented poor availabil-
ity of many anesthetic medicines, and data on the global availability of controlled medicines demonstrate poor (and in some cases, almost wholly absent) access predominantly in low- and middle-income countries, with multiple systemic barriers.\textsuperscript{11,12} Simply put, why is access to controlled medicines such a global failure, even in countries where there are celebrated and successful campaigns to improve access to medicines for other conditions, such as for the “big three” of HIV/AIDS, malaria and tuberculosis?

The answer is not intellectual property (or patents), though this is often said to be the major barrier to acquiring medicines at affordable prices. Of the anesthetics and analgesics present on the World Health Organization’s (WHO) Model List of Essential Medicines (EML), none has a currently valid patent, and many (such as morphine) are older medicines that can be manufactured and sold relatively inexpensively as generics.\textsuperscript{13,14} A more likely explanation for this lack of access is that many of these medicines are controlled under national and international law, which together constitute a barrier to reliable access, and may explain both documented and anecdotal accounts of poor access to and use of anesthetics and analgesics in surgical programs in developing countries.

Many essential medicines related to perioperative care are listed in one of the schedules of the three United Nations (UN) based international drug control treaties and controlled under national schedules (Table 1). Barriers to accessing controlled medicines, which include medicines for anesthesia, perioperative analgesia, palliative care, and even epilepsy, are rooted in a byzantine regulatory system that prioritizes restricting access to illicitly trafficked substances, over ensuring licit access to medicines. The cultural narrative and policy focus on the abuse potential of “drugs” trumps the valid medical uses of those same substances, and results in non-availability in the vast majority of low- and middle-income countries.

In this narrative review, we propose that the control systems themselves foster unduly restrictive laws, and that their complexity perpetuates providers’ lack of understanding and misinterpretations about the rational use of controlled medicines. To explain this hypothesis, we provide an overview of international and national drug control systems, focusing on controlled medicines, and how national and international laws and regulations contribute to restricting their availability. To illustrate how the international drug control system can potentially have a disastrous impact on safe anesthesia, we summarize a current and ongoing campaign to oppose attempts to place ketamine under more restrictive international controls.

**The International Drug Control System**

A suite of three multilateral treaties forms the basis of the international drug con-
control system: the 1961 Single Convention on Narcotic Drugs (as amended by the 1972 Protocol), which focuses primarily on plant based substances such as opium, cannabis, and cocaine; the 1971 Convention on Psychotropic Substances, which focuses on synthetic and non-plant based drugs including amphetamines, barbiturates and tranquilizers; and the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, which concentrates on the illicit trafficking of substances listed in the schedules of both its sister treaties, as well as on precursor substances. The genesis of these three treaties predates the 1961 Single Convention, which, as the name suggests, brought together a series of treaties that were developed since the first multilateral instrument addressing the drug issue, the 1912 International Opium Convention, was drafted. Initially concerned primarily with limiting the growing opium trade, these pre-war treaties addressed among other issues the non-medical trade in, diversion from pharmaceutical sources to illicit markets, and consumption of cocaine, heroin, and morphine.

Two UN bodies oversee the implementation of the three conventions. The Commission on Narcotic Drugs (CND) (comprised of 53 member states) is the central policy-making body of the United Nations drug control system, and the International Narcotics Control Board (INCB) is the 'quasi-judicial body' responsible for monitoring and enforcing member states’ implementation of the treaties. The United Nations Office on Drugs and Crime (UNODC) is the executive agency responsible for coordinating international drug control activities, and serves as the secretariat of the Commission on Narcotic Drugs. Figure 1 illustrates the various entities involved in drug control.

Substances under international control are listed under one of four schedules appended to each of the international treaties (hence the term “scheduling”). Unlike the 1961 and 1971 Conventions, the 1988 Trafficking Convention has a system of two ‘tables’ under which substances are classified. The CND alone does not have the authority to add a new substance to a schedule. The treaties require that the World Health Organization’s Expert Committee on Drug Dependence (ECDD) which conducts a thorough, evidence-based review following the request (called a notification) of a state party (a signatory to the relevant treaty) to review a substance. This process may also be initiated by the WHO itself. The ECDD review concludes with a recommendation either not to schedule, or to place the substances in one of the four schedules.

The ECDD, which is comprised of a diverse group of experts in pharmacology, clinical medicine, and other relevant disciplines, ensures at least in theory that the medical benefits of a substance are properly weighed against the public health or safety reasons to restrict or ban it. The Director General of the WHO then conveys the ECDD recommendation to the CND, which is bound to accept the recommendation of the WHO on
medical and scientific matters. The CND, however, may take other circumstances into account, such as legal and economic factors, when it votes on whether to place a substance under control. This flexibility has been contested and is discussed in the context of the recent proposal to place ketamine under international control. The intent of the scheduling process is to strike a balance by placing the substance within a continuum ranging from outright prohibition to varying degrees of restriction (which may involve no international controls at all). Each of the different schedules in the treaties reflects a stage in this continuum. Table 2 provides the criteria for each schedule under each treaty.

Scheduling a substance that has legitimate medical and scientific uses, however, poses its own difficulties. The Conventions establish an awkward mandate for countries to both restrict unlicensed access to such substances by regulating their manufacture, distribution, and possession, while also recognizing that the same controlled substances have legitimate scientific or medical uses for the relief of suffering. This vague double imperative has been interpreted as establishing a requirement to strike a balance between control and provision, yet the operational paragraphs of the Conventions provide no requirements or recommendations to states on how to properly ensure access to medicines and balance these mandates (yet contain several operational requirements on how to restrict access).

For example, while the Single Convention stipulates specific regulatory actions to restrict unlicensed access to narcotics, it is silent regarding the regulatory provisions necessary to advance legitimate scientific and medical access to substances under control. The result has been that countries over-emphasize criminal prohibition and under-emphasize, or entirely ignore, the need to provide access to scheduled medicines. Even the leadership of the INCB acknowledges this imbalance, and recent statistical modelling has shown that although consumption of opioid analgesics has more than doubled worldwide between 2001 and 2013, most of this increase has occurred in North America, western and central Europe, and Oceania, with countries in other regions (Africa, Asia, Central America, the Caribbean, South America, and eastern and southeastern Europe) showing no substantial increase in use.12,17

As non-self-executing treaties, the Conventions only establish a binding framework that signatories must then operationalize under their own domestic legal systems. Thus, while the Conventions represent an agreement on the controls deemed appropriate amongst member states, national authorities must translate this into national legislation specific to each country, for example the 1971 Misuse of Drugs Act in the United Kingdom,18 the 1970 Controlled Substances Act in the United States,19 and the 1996 Controlled Drugs and Substances Act in Canada.20
The Single Convention also establishes a system of import and export controls designed to limit and monitor the international trade of licit controlled narcotics. This system obliges governments to authorize and/or license any entities that participate in the trade or distribution of these medicines, including pharmaceutical companies, distributors, and pharmacists. Each transaction has to be recorded in detail, and all transactions are subject to a quota imposed on each country by the INCB as a result of that country’s annual provision of estimates of the quantities of controlled medicines required. Countries must also provide quarterly data on imports and exports of narcotic drugs. All this documentation is onerous, especially for less developed countries, and can significantly impact the availability of opioid analgesics.

For example, the Single Convention requires countries to submit estimates of their annual requirements for controlled medicines, which establishes the quantity of these medicines that each country can legally import in the coming year. The INCB is supposed to confirm the estimates are reasonable, given the Single Convention’s dual mandate, but in practice the INCB frequently confirms estimates that are well below what could reasonably be presumed to be the actual medical need based on the burden of disease. This is arguably because of a lack of capacity within countries to properly estimate their annual requirements and a lack of capacity within weak health systems to properly manage pain. The confirmation of unrealistically low estimates by the INCB is, at best, questionable. At worst, it is a violation of their treaty-mandated role to ensure that parties comply with the aims of the convention, one of which is to ensure adequate access.

Chad, for example, is allocated 61 grams of fentanyl, 160 grams of morphine, 35 grams of codeine, and 1 gram of normethadone for a country of 13.5 million people. This compares to Canada, whose consumption of controlled medicines is among the highest in the world and is allowed 59 controlled substances, including 150,000 grams of fentanyl, 4,000,000 grams of morphine, 33,392,500 grams of codeine, and 20,000 of normethadone for a population that is slightly more than twice that of Chad. This disparity in access is arguably multifactorial, and previous studies have demonstrated barriers including an absence of awareness or training in the use of opioid medicines, fears of addiction, issues in sourcing from industry or imports, and other systemic barriers that need to be addressed. This should include, but goes beyond, the INCB’s status of estimates system.

After the INCB confirms the estimates, states have to comply with other complex bureaucratic requirements, particularly for medicines included in the schedules of the 1961 Convention. For each shipment of medicines, the importing country must issue an import license to a pharmaceutical supplier, who must send the license to the competent authorities in the exporting country. The competent authorities verify its authenticity, sometimes by contacting the INCB, and decide whether the importing country remains
within the quota established through the confirmed estimates. A single mistake can result in having to repeat the entire process, which several organizations have highlighted as the cause of delays of months to years in obtaining single shipments of controlled medicines such as morphine or pethidine.\textsuperscript{22}

Similar requirements exist for the substances controlled under the 1971 \textit{Convention on Psychotropic Substances}.\textsuperscript{23} In general, the 1971 Convention is less stringent, due in large part due to political maneuvering during the drafting and negotiation of the treaty. This process was driven by the high income countries of the ‘Global North’ who lobbied for less stringent controls on behalf of their domestic pharmaceutical industries, and preferred to maintain access to synthetic medicines such as benzodiazepines, rather than plant-based materials such as opium or cannabis.\textsuperscript{24}

Thus the treaties have explicitly set up barriers to access to medicines containing controlled substances, barriers that have no parallel in public health. While many other prescription medicines have bad, or arguably worse, public health effects if abused (e.g. antibiotics and antimicrobial resistance), only narcotics and psychotropic medicines are subject to the degree of reporting required by these treaties. For less developed countries and health systems plagued by chronic human and physical resource shortages, the workflow of tracking all the controlled substances entering or circulating in the country is effectively an impossible task and an error may result in severe criminal punishment. As a result, providers must function with negligible access to these and other essential anesthetic medicines, or must risk being non-compliant, a risk few are willing to take.

\textbf{National Scheduling of Medicines}

The Conventions could be viewed as a set of minimum standards for drug control, whereby countries must meet a baseline set of obligations. However, the national legislation of many countries actually exceeds these standards. A recent review of legislation in 11 Central and Eastern European countries, for example, identified legal barriers in the prescribing of opioids in all of the nations studied, while 10 countries included dispensing barriers and used stigmatizing language to describe controlled medicines.\textsuperscript{25} This included language that overemphasized the addictive nature of opioids or severely restricted pharmacists’ ability to dispense medications, for example restricting the dispensing of opioids prescribed by physicians from a different city.

Furthermore, there are often discrepancies between international scheduling requirements and national legislation. Although both the 1971 and 1961 Conventions both contain four schedules, national drug control laws may not offer similar degrees of nuance. Kenya, for example, has only three schedules, each one providing only one level of
control for narcotic drugs, psychotropic substances, and prohibited plants. Thus, although the intention of international scheduling is to provide some nuance and gradients in the restrictions imposed upon essential medicines, the treaties do not require parties to reproduce these nuances at the national level.

Restrictive national laws and policies with devastating effects have been documented in several countries. In Ukraine, Human Rights Watch documented a grossly inadequate and cumbersome system that restricted access to effective palliative care for terminally ill patients in pain. This included policies that prohibited patients who were not receiving curative care from being admitted to hospital and required healthcare workers to directly administer opioid medications to patients (rather than leaving a supply for patients or families to administer). Because of a lack of oral morphine in the country, healthcare workers were required to travel to patients’ homes six times a day to administer injectable morphine, a requirement that was near impossible to meet, resulting in an unnecessary barrier to effective pain relief for patients with moderate to severe pain.

In a related publication, Human Rights Watch found that Armenian domestic legislation allows only cancer patients to receive opioids as outpatients. Only oncologists are allowed to prescribe, and prescriptions require the approval of a standing commission comprised of the patient’s oncologist, the chief and/or deputy chief doctor of one of the 13 polyclinics authorized to prescribe opioids, the chief nurse, general practitioner, and sometimes up to two other physicians in the polyclinic. Additional requirements include the use of a special government approved form that must be stamped by four involved physicians and clinics. Although anesthesiologists help train oncologists in pain management, they are not allowed to prescribe opioids to outpatients.

India provides an example of how restrictive national laws can be reformed, although it is too soon to determine how effective these reforms have been in improving availability. India’s earlier previous narcotics control law, the Narcotic Drugs and Psychotropic Substances (NDPS) Act of 1985, instituted excessively burdensome licensing procedures for accessing opioid analgesics. Each state had different rules requiring pharmacists and doctors to procure four to five different licenses before they could prescribe or dispense morphine to patients. These licenses required the approval of multiple government departments, and each needed to be valid at the same time. Even minor errors in bookkeeping could result in significant penalties. Following ratification of the 1985 Act (which India had to promulgate in order to comply with the provisions of the Single Convention), the consumption of morphine in the country dropped from an already low level of 573 kg in 1985, to 17 kg in 1997.

Concerted and vigorous pressure from civil society ensured that the NDPS Act was
subsequently reformed in 2014, shifting the power for the legislating control of opioid analgesics from the states to the central government. Now, health providers need only a single governmental approval from a single agency is necessary to for procure and dispense morphine. The amended Act is applicable but has not yet reached the implementation stage throughout the country. Hence, many states continue to have the 5 license requirements and the punishment for an error (e.g., even one license beyond the expiry date is still harsh - 10 years in prison). Moreover, there is no proportionality in punishment for the alleged crime: a discrepancy of few milligrams of opioid medicine stock in a hospital is equivalent to possession of a few kilograms of an illicitly trafficked substance for the purpose of criminal proceedings.

We are unaware of a systematic analysis of the impact of national drug control policies on access to anesthetics and analgesics in hospital settings. The impact of these policies on community- or primary-care settings, particularly for palliative care, have been well-described, the impact on the availability of medicines in hospitals with surgical capacity is less clear, though several analyses have documented shortages of essential anesthetics, including controlled medicines, in hospital settings. Further research is needed to determine the cause of anesthetic medicine stock-outs, though in surveys of anesthetic and surgical capacity, several note that narcotic analgesics are infrequently, or never, available, further suggesting that the barriers to accessing controlled medicines differ from non-controlled medicines. These barriers to access need to be further explored to determine where the barriers exist, including examining what barriers exist at the provider, health system, and legislative levels.

**Recent Experiences with a Proposal to Schedule Ketamine**

Ketamine is an N-methyl-D-aspartate receptor antagonist that is commonly used around the world for anesthesia, procedural sedation, and acute and chronic pain control. It is a particularly useful medication as it provides dissociative anesthesia and analgesia without a significant loss of airway protection, respiratory drive or cardiovascular stability; it also has a wide therapeutic index. In many operating rooms in low-income countries, there is no physician anesthetist present; instead, ketamine anesthesia is often administered by a nurse, operating room assistant, or even by the surgeon who is simultaneously performing the operation. Because of its unique properties and broad range of applications, ketamine is listed on the World Health Organization’s Model List of Essential Medicines.

Many hospitals in LMICs lack both mechanical ventilators and sophisticated monitoring equipment. The cardiovascular stability and relatively intact respiratory drive under ketamine anesthesia make it possible to use this medication without a mechanical ventilator and even when only minimal monitoring is available. For example, a
recent survey in Mongolia determined that only 1 in 5 hospitals routinely employ perioperative capnography. In cases of extreme resource shortages such as disaster relief efforts, equipment can be even more limited. Healthcare workers indicated that during the response to the 2010 earthquake in Haiti, some emergency procedures under ketamine sedation were monitored with just “chest excursion, color, carotid pulse, and manual arterial blood pressure measurement”. Thus, the good safety profile of ketamine makes it indispensable in these resource-limited settings. A recent review of a ketamine anesthesia protocol in rural hospitals by non-physician anesthesia providers examined 193 consecutive surgical procedures. They identified no major adverse events and only a small number of minor adverse events (brief desaturation of <30 seconds in 8.6% of patients and hallucinations in 12.1%), providing further evidence of the utility of this medicine in safe anesthetic care in resource-limited settings.

In addition to its safety profile, ketamine is an affordable generic medicine. It is portable and stable, which make it practical for use in remote areas and disaster relief efforts. In a campaign supported by the World Federation of Societies of Anesthesiologists, frontline healthcare workers have repeatedly noted the crucial role of ketamine in providing life-saving procedures in LMICs; this sentiment was echoed by the ECCD, which stated that reducing the availability and accessibility of ketamine “in turn would limit access to essential and emergency surgery, which would constitute a public-health crisis in countries where no affordable alternative anesthetic is available”.

Many of the properties that make ketamine useful as an anesthetic also make it appealing as a recreational hallucinogen. Ketamine has long been recognized as a drug of misuse, with reports of recreational use appearing in the medical literature shortly after its introduction into medical practice in the 1970s. In this regard, the drug produces effects that are similar to other psychedelic drugs, specifically phencyclidine, or PCP, of which ketamine is a derivative, though it has a briefer duration of action than most other drugs such as lysergic acid diethylamide (LSD). Non-medical use appears to be particularly widespread in South-East Asia, especially in China.

The International Narcotics Control Board and several member states have responding to this non-medical use by calling for the CND to place ketamine under international control. In 2004, despite arguably exceeding its mandate, the INCB asked the “international community to give serious consideration to initiating the procedure” for placing ketamine under international control, and also called on the WHO to expedite its ECDD review of the medicine. This growing momentum, fueled in large part by the INCB and several member states, has by-and-large ignored the impact that scheduling would have on access to ketamine for medical use in low-income, low-resource settings.
This process has been controversial, because ketamine is an essential medicine whose absence in anesthetic carts would place millions of the world’s poorest patients in the cruel position of having to choose between foregoing surgical procedures due to lack of anesthetic, or undergoing surgery without it. Furthermore, the UN drug control agencies have been marginalizing the WHO, whose treaty based role is crucial and has direct bearing on global health, particularly with regard to the 1971 Convention on Psychotropic Substances.\textsuperscript{57}

In 2014, the government of China notified the Secretary-General of the United Nations to recommend that ketamine be placed in Schedule I of the 1971 Convention.\textsuperscript{58,59} This followed the passage of a non-binding resolution proposed by Thailand and passed by vote of the member states at the 2014 Commission on Narcotic Drugs calling for member states to pursue national scheduling. The impact of this resolution was mitigated by statements of several key member states that opposed listing ketamine under international schedules out of concern that doing so would restrict medical access.\textsuperscript{60} Following China’s notification that it intended to pursue international scheduling of ketamine, the ECDD conducted a third review of the medicine. It once again recommended against scheduling due to a lack of evidence of widespread, international misuse sufficient to balance against the restrictions that would be imposed on medical availability of the drug, likely limiting its use in anesthetic practice. The review was externally peer-reviewed by experts, with one reviewer warning that scheduling would create a “global public health crisis” should ketamine become unavailable as the anesthetic of necessity in resource-poor settings.\textsuperscript{50} This ECDD review was subsequently updated in November 2015 and similar recommendations were made.

The 1971 Convention states that WHO has sole authority to make determinations as to whether there is sufficient evidence “…warranting the placing of [a] substance under international control,” in a medical and scientific context, notes that on these matters, WHO’s “assessments shall be determinative.”\textsuperscript{61} The ECDD has reviewed ketamine four times, including an update in November 2015, and has repeatedly found that scheduling of ketamine would not be appropriate. The WHO has communicated this to the CND, and given that placing restrictive international controls on an essential medicine used to provide basic surgical care to billions in poor countries is clearly a medical issue, WHO’s decision should have been final. However, the CND, acting on legal advice provided by the UNODC, still initiated the scheduling process by placing it on the agenda of the CND, arguing that it may consider economic, social, legal, administrative and other factors it deems relevant. This position remains controversial.

China initially requested ketamine be listed as a Schedule I substance, which by definition refers to a substance with no legitimate medical or scientific use and, therefore,
requires the imposition of stringent restrictions. This was a remarkable proposal given the medicine’s widespread and diverse therapeutic uses. In response, a significant international challenge was mounted by the global anesthesia, surgery, and veterinary medicine communities, supported by numerous health and human rights organizations to oppose this proposal. The resultant effect was dramatic, including a widely disseminated and broadly endorsed fact sheet on ketamine, and several member states actively opposed the Chinese proposal. In the end, China relented, initially altering its proposal to list ketamine under the less restrictive Schedule IV, rather than Schedule I, and finally opting to defer the vote to a later date, likely because of an obvious lack of support for the proposal. The possibility of pursuing the scheduling of ketamine still remains, and the matter is not closed, though in November 2015 the WHO Expert Committee on Drug Dependence once again updated its review of ketamine and reaffirmed its decision that it not be placed under international control.

The subject re-emerged at the regular session of the 59th Commission on Narcotic Drugs in 2016, with China once again proposing to defer a decision as to whether to place ketamine under international control, meaning that the notification remains alive and could be pursued with little notice at subsequent sessions. Furthermore, although there was no explicit proposal on the agenda to place ketamine in one of the international schedules, the Chinese delegation attempted to include references to ketamine in a resolution calling for voluntary controls on new psychotropic substances. The resolution included language urging pre-export and other controls on states parties, thereby introducing something close to ‘scheduling by resolution’ - a backdoor mechanism of restricting access and one that lies outside the provisions of the international drug control conventions. China’s attempt to include ketamine in the resolution ultimately failed, thanks to strong resistance from the same member states that opposed the formal measure in 2015.

The mechanics of this scheduling proposal and subsequent campaign are complex, and grounded in international drug control law – unfamiliar territory for many anesthesiologists and health professionals. Yet, it highlights the importance of an elementary understanding of international and national scheduling and the need to maintain an active voice in these international fora that have the potential to drastically impact on the delivery of safe anesthetic care for billions in low-income countries.

Discussion

Significant disparities remain in accessing safe and effective surgical care, with the world’s poorest being disproportionately disadvantaged by low levels of service availability. Addressing this disparity requires coordinated action to ensure that safe surgery and anesthesia are no longer neglected as essential health services. There are signs that this is changing: the World Health Assembly, in 2015, passed resolution 68.15, recognizing the importance of surgery and anesthesia as a component of universal health
coverage, which was a significant political advance.71 Realizing the impact of this resolution, however, will require significant movement on the ground to comprehensively and sustainably integrate surgical services into health systems in low-income countries, for which there is little guidance.10 A key component of this will be to ensure the reliable availability of high-quality anesthetic and analgesic medicines.

Anesthesia is uniquely affected by national and international drug control laws, with 15 of the 46 anesthesia and analgesia-related essential medicines listed in the categories of: Anaesthetics, Medicines for Pain and Palliative Care, or Anticonvulsants/antiepileptics (all of which have some crossover into clinical anesthesia) also being under international control through one of the three drug control conventions (table 1).14,15 Although the availability of medicines is obviously inseparable from the practice of anesthesia, relatively little work has been done to document the availability of both controlled and uncontrolled anesthetics and the barriers to obtaining them in health systems in low-income countries. A recent systematic review of the integration of surgical care into health systems identified a lack of medicines for surgical care as a concern, but provided no analysis of the reasons for the poor availability.10

Ensuring access to these medicines should, therefore, be a foundational component of programs to improve the availability of surgery and anesthesia in low-income countries. Without the availability of high-quality anesthetics and analgesics, the scaling-up of global surgical capacity is near-impossible.

It is important to recognize that the restrictions that result from national and international controls (“scheduling”) of medicines are feasible and reasonable in many high-income countries for controlling inappropriate access to substances with the potential to produce harm, and the judicious and responsible use of controlled medicines is essential. However, these restrictions must be reasonable and must ensure the appropriate availability of medicines under national or international control. Several high-income countries have placed ketamine under national control with no apparent systemic adverse effects for appropriate medical access, though it must also be recognized that, in contrast with the situation in low-income countries, ketamine is not the anesthetic agent of choice or necessity in most circumstances in high-income countries. However, currently, controlled medicines are disproportionately inaccessible in low- and middle-income countries relative to uncontrolled medicines and relative to high-income countries with competent and functioning regulatory systems. Complying with the regulatory requirements of these national and international systems are onerous, and given that most controlled medicines are older generic medicines for which profit margins are generally small, the costs associated with compliance are proportionally significant, and likely serves as a deterrent to many companies who may simply withdraw products from markets rather than shoulder
the costs and burdens of compliance. At present, there does not appear to be a model of how to place a medically-necessary substance under national or international control while simultaneously ensuring its rational availability for medical purposes in low- and middle-income countries, despite the fact that such a balance is the intention of the international drug control regime and the conventions on which it is founded.

The barriers to accessing adequate pain management, however, do not reside exclusively in regulatory or legislative systems. Health professionals require the knowledge and training to successfully implement these interventions into patient care in low-income countries, and significant work remains to be done to counter false or exaggerated perceptions of the harms associated with opioid analgesic use and to ensure that pain management is consistently provided as part of perioperative care, and that the medicines to do so are consistently and appropriately available.

The experience, knowledge and awareness gained by the global anesthesia community by opposing the ketamine scheduling proposal should be but a starting point for addressing the broader access constraints plaguing anesthesia and surgical providers and patients in low-income countries. This experience points to the need for the anesthesia community to serve as advocates for access to essential medicines and to more comprehensively understand how existing systems impact on the availability of anesthetics and the delivery of patient care.

Conclusions and future directions

The inadequate treatment of pain for over 5 billion people is arguably one of the greatest tragedies in global health. While substantial work has been done to understand and address the barriers to accessing analgesics for palliative care, little work has been done to improve access to controlled medicines for anesthesia. As global surgery gains momentum with national governments, international donors, and aid organizations, there is an urgent need to ensure that anesthesia providers advocate for access to essential medicines. This includes campaigning to redress the barriers to accessing controlled medicines, which form a sizable proportion of the medicines used in the provision of clinical anesthesia. The anesthesia community has not had a presence at important moments in controlled medicine policy, such as the Commission on Narcotic Drugs or the United Nations General Assembly Special Session on Drugs, but should. Anesthesia providers should have a strong, visible presence at international drug control meetings, and should work with other medical communities who have been active in this area, specifically palliative care, to ensure that national and international drug control policies place a strong emphasis on access to controlled medicines to improve the availability and quality of safe anesthetic care for patients in low- and middle-income countries.
References


**Table 1 – Anesthetic and Analgesic Medicines Under International Control***

<table>
<thead>
<tr>
<th>Medication</th>
<th>International Treaty Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cocaine</td>
<td>SCND (Schedule I)</td>
</tr>
<tr>
<td>Codeine</td>
<td>SCND (Schedule II)</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>CPS (Schedule IV)</td>
</tr>
<tr>
<td>Diazepam</td>
<td>CPS (Schedule IV)</td>
</tr>
<tr>
<td>Ephedrine*</td>
<td>CAITNDPS (Table I)</td>
</tr>
<tr>
<td>Ergotamine</td>
<td>CAITNDPS (Table I)</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>SCND (Schedule I)</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>CPS (Schedule IV)</td>
</tr>
<tr>
<td>Methadone*</td>
<td>SCND (Schedule I)</td>
</tr>
<tr>
<td>Midazolam</td>
<td>CPS (Schedule IV)</td>
</tr>
<tr>
<td>Morphine</td>
<td>SCND (Schedule I)</td>
</tr>
<tr>
<td>Oxycodone*</td>
<td>SCND (Schedule I)</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>CPS (Schedule IV)</td>
</tr>
<tr>
<td>Remifentanly</td>
<td>SCND (Schedule I)</td>
</tr>
<tr>
<td>Sufentanly</td>
<td>SCND (Schedule I)</td>
</tr>
</tbody>
</table>

Medicines highlighted in green are also listed on the World Health Organization’s 19th Model List of Essential Medicines. *listed as an alternative or complementary medication on Model List. SCND = Single Convention on Narcotic Drugs, CPS = Convention on Psychotropic Substances, CAITNDPS = Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances
Table 2 – Definitions of Controlled Substance Schedules

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Schedule I</strong></td>
<td><strong>Schedule I</strong></td>
<td><strong>Table I</strong></td>
</tr>
<tr>
<td>Substances that are highly addictive and liable to abuse, or are convertible into drugs that are similarly addictive and liable to abuse</td>
<td>Substances presenting a high risk of abuse, posing a particularly serious threat to public health, which are of very little or no therapeutic value</td>
<td>Precursors of psychotropic substances and key reagents use in the conversion and extraction of narcotic drugs and psychotropic substances</td>
</tr>
<tr>
<td><strong>Schedule II</strong></td>
<td><strong>Schedule II</strong></td>
<td><strong>Table II</strong></td>
</tr>
<tr>
<td>Substances that are less addictive and liable to abuse than those in Schedule I</td>
<td>Substances presenting a risk of abuse, posing a serious threat to public health, which are of low or moderate therapeutic value</td>
<td>Reagents and solvents which can be used in the illicit production of narcotic drugs and psychotropic substances, but also have widespread industrial uses</td>
</tr>
<tr>
<td><strong>Schedule III</strong></td>
<td><strong>Schedule III</strong></td>
<td></td>
</tr>
<tr>
<td>Preparations containing narcotic drugs that are intended for medical use and are unlikely to be abused</td>
<td>Substances presenting a risk of abuse, posing a serious threat to public health, which are of moderate or high therapeutic value</td>
<td></td>
</tr>
<tr>
<td><strong>Schedule IV</strong></td>
<td><strong>Schedule IV</strong></td>
<td></td>
</tr>
<tr>
<td>Certain drugs listed in Schedule I that are highly addictive and liable to abuse and rarely used in medical practice</td>
<td>Substances presenting a risk of abuse, posing a minor threat to public health, with a high therapeutic value</td>
<td></td>
</tr>
<tr>
<td><strong>Schedule V</strong></td>
<td><strong>Schedule V</strong></td>
<td></td>
</tr>
<tr>
<td>Substances that have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics</td>
<td>Substances presenting a risk of abuse, posing a minor threat to public health, with a high therapeutic value</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1 – Entities in the United Nations Drug Control System

United Nations

Economic & Social Council

Functional Commissions

Commission on Narcotic Drugs
53 Member States
Non-Medical

INCB
UNODC

Special Agencies

World Health Organization
194 Member States

Expert Committee on Drug Dependence
18 Individual Appointed Members
Medical & Pharmaceutical